Design Therapeutics Stock Alpha and Beta Analysis
| DSGN Stock | USD 3.78 0.02 0.53% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Design Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Design Therapeutics over a specified time horizon. Remember, high Design Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Design Therapeutics' market risk premium analysis include:
Beta (0.11) | Alpha 0.79 | Risk 4.61 | Sharpe Ratio 0.17 | Expected Return 0.77 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Design |
Design Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Design Therapeutics market risk premium is the additional return an investor will receive from holding Design Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Design Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Design Therapeutics' performance over market.| α | 0.79 | β | -0.11 |
Design Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Design Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Design Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Design Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Design Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Design Therapeutics shares will generate the highest return on investment. By understating and applying Design Therapeutics stock market price indicators, traders can identify Design Therapeutics position entry and exit signals to maximize returns.
Design Therapeutics Return and Market Media
The median price of Design Therapeutics for the period between Sun, Jan 28, 2024 and Sat, Apr 27, 2024 is 2.85 with a coefficient of variation of 20.03. The daily time series for the period is distributed with a sample standard deviation of 0.61, arithmetic mean of 3.03, and mean deviation of 0.55. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC Therapy for the Treatment of Fuchs ... - Marketscreener.com | 02/23/2024 |
2 | RTW Investments LP Boosts Stock Position in Design Therapeutics, Inc. - MarketBeat | 03/06/2024 |
3 | Disposition of 175000 shares by Kim Jae B. of Design Therapeutics at 2.54 subject to Rule 16b-3 | 03/13/2024 |
4 | Acquisition by Xu Stella of 44398 shares of Design Therapeutics subject to Rule 16b-3 | 03/14/2024 |
5 | Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results | 03/19/2024 |
6 | Design Therapeutics, Inc. Q4 2023 Earnings Call Transcript | 03/20/2024 |
7 | Acquisition by Schmid John P. of 9156 shares of Design Therapeutics at 3.6187 subject to Rule 16b-3 | 03/22/2024 |
8 | Acquisition by Berger Heather A. of 1300 shares of Design Therapeutics at 3.7429 subject to Rule 16b-3 | 03/25/2024 |
9 | Design Therapeutics And 2 Other Stocks Under 5 Insiders Are Buying | 03/26/2024 |
10 | Disposition of 7236938 shares by Quan Venture Fund Ii, L.p. of Design Therapeutics subject to Rule 16b-3 | 04/11/2024 |
11 | Acquisition by Prasad Deepa of 15000 shares of Design Therapeutics at 5.63 subject to Rule 16b-3 | 04/25/2024 |
About Design Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Design or other stocks. Alpha measures the amount that position in Design Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Graham Number | 0.0115 | 0.011 | Receivables Turnover | 0.0203 | 0.0181 |
Design Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Design Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Design Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Design Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Design Therapeutics. Please utilize our Beneish M Score to check the likelihood of Design Therapeutics' management manipulating its earnings.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Design Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Design Therapeutics Backtesting, Design Therapeutics Valuation, Design Therapeutics Correlation, Design Therapeutics Hype Analysis, Design Therapeutics Volatility, Design Therapeutics History and analyze Design Therapeutics Performance. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.Note that the Design Therapeutics information on this page should be used as a complementary analysis to other Design Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Design Stock analysis
When running Design Therapeutics' price analysis, check to measure Design Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Design Therapeutics is operating at the current time. Most of Design Therapeutics' value examination focuses on studying past and present price action to predict the probability of Design Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Design Therapeutics' price. Additionally, you may evaluate how the addition of Design Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Design Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.